Blood cancer patients on Bruton's tyrosine kinase inhibitors should continue at time of COVID-19 vaccination, study says
Blood cancer patients who receive a type of anti-cancer therapy should continue to take the drug while having COVID-19 ...
Medscape20h
Phase 2 Trial Supports TYK2 Inhibitor for Cutaneous Lupus, Paving Way for Pivotal Trials
After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...
Labiotech.eu6d
A guide to kinase inhibitors in biotech: From cancer breakthroughs to autoimmune innovations
Delve into the kinase inhibitors' diverse landscape, from cancer breakthroughs to autoimmune disease innovations.
Health and Me on MSN10h
FDA Approves Cabozantinib For Neuroendocrine Tumors
The approval came on the bases of the results from the phase 3 CABINET study. The study compared cabozantinib to a placebo in ...
FDA approves cabozantinib for previously treated advanced neuroendocrine tumors
The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients ...
Medscape1d
Osimertinib OS Benefit Persists Among Patients With EGFR+ NSCLC
OS for osimertinib vs placebo was 58.8 vs 54 months at the latest analysis of the phase 3 LAURA trial, according to ...
CURE2d
What Patients With Kidney Cancer Need to Know From ASCO GU
There were a number of notable developments for patients with kidney cancer at the symposium, Dr. Emre Yekedüz explained.